(Q36283744)

13 August 2017

1 reference

title

Update on linezolid: the first oxazolidinone antibiotic (English)

1 reference

13 August 2017

0 references

1 reference

1

Mark H Wilcox

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

13

1 reference

13 August 2017

page(s)

2315-2326

1 reference

Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid--a review of the first oxazolidinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid: a review of its use in the management of serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

A review of linezolid: the first oxazolidinone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Healthcare-associated pneumonia in adults: management principles to improve outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Antimicrobial resistance to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid in the treatment of osteomyelitis: results of compassionate use experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid use associated with lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Serotonin syndrome due to co-administration of linezolid and venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Serotonin syndrome and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Enterococcal vanB resistance locus in anaerobic bacteria in human faeces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Characterization of a Tn5382-like transposon containing the vanB2 gene cluster in a Clostridium strain isolated from human faeces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Human intestinal bacteria as reservoirs for antibiotic resistance genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

The use and therapeutic drug monitoring of teicoplanin in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Pharmacokinetics of linezolid in subjects with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.13.2315

10.1517/14656566.6.13.2315

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference